Sponsored By Since it was so important, I want to recap last week’s big Alzheimer’s news again. If you recall, lecanemab's developers were among the biggest stock market beneficiaries of Clarity-D’s topline readout, but...
“How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.”
— Robert G. Allen
SNPX
Synaptogenix Latest Press Release
Latest SNPX Press Release
Betting on SNPX
Sponsored By Hello again, Trader! Yes, I’ve been talking a lot about Synaptogenix (SNPX) lately, and yes, I know the trading has been disappointing to say the least the last few days. In times like this when the market tests...
Could a cure be around the corner 🤔
Sponsored By Do you know someone suffering from Alzheimer’s or has lost their fight with it? It’s likely you do, as 1 in 3 seniors dies with Alzheimer's (AD) or another dementia -- which kill more than breast cancer and...
🤞🙏🤞Dr. Alkon hopeful for an Alzheimer’s breakthrough
Sponsored By Dear Traders- Jeff Bishop here! If you’ve been following our updates you know we’ve been featuring Synaptogenix (SNPX) and its lead therapeutic candidate Bryostatin-1 for the treatment of the disease we all know...
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network
PR Newswire NEW YORK , Aug. 12, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that Dr. Daniel L. Alkon , the...
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data
PR Newswire Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK , July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...
Synaptogenix Announces Corporate Update Conference Call
PR Newswire NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate...
Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer’s Disease Trial Data
Published: Jul 20, 2022 Dose optimization prepares the Company for its next phase of Bryostatin clinical development Company expects to announce topline data from its NIH sponsored Phase 2 clinical study during the fourth quarter of 2022 NEW YORK, July 20,...